Penthrox® Europe
Penthrox® Europe

This website is an information resource intended for healthcare professionals only.

I am a healthcare professional

Patients who have been given Penthrox® can find the Patient Information Leaflet (PIL) here.

Report adverse events

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of medicine.

Mundipharma routinely monitors the safety of all its medicines, including reviewing safety data from clinical studies and collecting reports of adverse events. If you are a patient or are aware of a patient who has experienced an adverse event, overdose or unexpected benefits with one of our products, please also contact Mundipharma by calling +44 (0) 1223 424 211 or by emailing eudrugsafety@mundipharma-rd.eu. Mundipharma will only use your details to contact you about your adverse event report.

Penthrox is a registered trademark of Medical Developments International Limited and is used under licence. The Mundipharma network of independent associated companies has exclusive rights in 40 European countries, but excluding the UK and Ireland.

Copyright © 2018 Mundipharma International Limited. All rights reserved.

Mundipharma

References

  1. Penthrox SmPC, 2015.
  2. Coffey F et al. Emerg Med J 2014;31:613–18.
  3. Dayan AD. Hum Exp Toxicol 2016;35:91–100.
  4. Safe use of opioids in hospitals, 2012.
  5. Oxer HF. Prehosp Disast Mrf 2002;17:s61–62.
  6. Todd KH et al. J Pain 2007;8:460–66.
  7. MDI. Data on file. STOP! Study Clinical Study Report. 2014.
  8. Hwang U et al. Acad Emerg Med 2008;15:1248–55.
  9. Tanabe P & Buschmann M. J Emerg Nurs 1999;25:171–7.
  10. Sokoloff C et al. BMJ Open 2014;4:e004288.
  11. Coffey F et al. Adv Ther 2016;33(11):2012 –31. doi:10.1007/s12325-016-0405-7.
  12. Tveita T et al. Acta Anaesthesiol Scand 2008; 52:920–25.
  13. Mercadante S et al. Curr Med Res Opin2009;25:11,2805–15.
  14. Oxer HF. Journal of Military and Veterans’ Health 2016;24:14–20.
  15. MDI. Data on file. Determining when Penthrox is empty. 2016.
  16. Tomi K et al. Br J Anaesth 1993;70:684–6.
  17. Middleton PM et al. Prehosp Emerg Care 2010;14:439–47.
  18. Charbek E, Christensen, B. Normal vital signs. http:// emedicinemedscapecom/article/2172054-overview (Accessed May 2017).
  19. MDI. Data on file. Recycling of Penthrox. 2017.
  20. MDI. Data on file. Stability of Penthrox. 2016.
  21. Windsor J et al. High Alt Med Biol 2009;10:201–2.
  22. Ellerton J et al. High Alt Med Biol 2014;15:8–14.
  23. Karuri AR, Agarwal RK, Engelking LR, Kumar MS. Brain Res Bull 1998;45:501–6.
  24. Nguyen NQ et al. Endosc Int Open 2015;3:E487– 93.
  25. Major V, Rosen M, Mushin WW. Br Med J 1967;4:767–70.
  26. Rosen M, Mushin WW, Jones PL, Jones EV. Br Med J 1969;4:432–3.
  27. Jones PL, Rosen M, Mushin WW, Jones EV. Br Med J 1969;3:255–9.
  28. Latto IP, Rosen M, Molloy MJ. Br J Anaesth 1972;44:391–400.
  29. Anwari JS, Khalil L, Terkawi AS. Saudi J Anaesth 2015;9:370–5.
  30. Entonox summary of product characteristics http:// www.mhra.gov.uk/spc-pil/?prodName=ENTONOX%20MEDICINAL%20GAS&subsName=NITROUS%20 OXIDE&pageID=SecondLevel (accessed October 2016).
  31. Bendall JC, Simpson PM, Middleton PM. Prehosp Emerg Care 2011;15:158–65.
  32. Gillis M et al. Regional Anesthesia and Pain Medicine 2008;33:e247 (poster 411).
  33. Buntine P, Thom O, Babl F, Bailey M, Bernard S. Emerg Med Australas 2007;19:509–14.
  34. Frangos J, Mikkonen A, Down C. Regul Toxicol Pharmacol 2016;80:210-25.
  35. Penthrox Product Information. www.medsafe.govt.nz/ profs/Datasheet/p/penthroxinh.pdf (Accessed April 2016)
  36. MDI. Data on file. Flammability of Penthrox (methoxyflurane). 2017.
  37. MDI. Data on file. Methoxyflurane Material Safety Data Sheet. http://www.medicaldev.com/penthrox-msds/. (Accessed October 2016) 73.
  38. Tomlin PJ. Methoxyflurane. Br J Anaesth 1965;37:706–9.
  39. Mazze RI, Trudell JR, Cousins MJ. Anesthesiology 1971;35:247–52.
  40. Cousins MJ, Mazze RI. JAMA 1973;225:1611–6.
  41. Jacobs IG. Open Emerg Med J 2010;3:7–13.
  42. MDI. Data on file. Nephrotoxicity. 2013.
  43. Federal Drug Administration. Determination that Penthrane (methoxyflurane) inhalation liquid, 99.9 percent, was withdrawn from sale for reasons of safety or effectiveness. http://www.fda.gov/ohrms/dockets/98fr/05-17559.htm [accessed July 2016].
  44. Federal Drug Administration (FDA). Federal Register August 16th 2001 http://wwwfdagov/OHRMS/ DOCKETS/98fr/081601ahtm (Accessed July 2016).
  45. Crandell WB, Pappas SG, Macdonald A. Anesthesiology 1966;27:591–607.
  46. Mignault G, Labrecque B, Hamel S. Can Anaesth Soc J 1970;17:331–40.
  47. Jones NO. Can Anaesth Soc J 1972;19:152–9.
  48. Urgena RB, Gergis SD. Br J Anaesth 1973;45:358–62.
  49. Hagood CO, Jr., Kemmerer WT, Jackson B. Am J Surg 1973;125:786–8.
  50. Desmond JW. Can Anaesth Soc J 1974;21:294–307.
  51. Hamilton WF, Robertson GS, Campbell D. Br J Anaesth 1975;47:508–11.
  52. Rosen M, Asscher AW, McLachlan MS, Williams LA. Br J Anaesth 1974;46:827–8.
  53. Porter K et al, Open Access Emergency Medicine 2018:10 149-164.